跳至主要内容
临床试验/NCT03143517
NCT03143517已完成不适用

CALFE Stool Sample Collection Protocol

DiaSorin Inc.13 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2017年4月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
DiaSorin Inc.
入组人数
240
试验地点
13
主要终点
Calprotectin Stool Collection

研究概览

简要总结

The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study. Eligible subjects require a diagnostic colonoscopy with possible biopsy and clinical evaluation.

详细描述

Stools will be collected and tested, at a later date, in a clinical performance study with an investigational Calprotectin assay. This study will be coordinated by the Sponsor.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
4 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is of either gender and ≥ 4 years of age.
  • Subject is showing signs and symptoms of IBD and/or IBS.
  • Diagnosis of IBD, IBS or other gastrointestinal disorder is performed by colonoscopy.
  • Subject or authorized legal representative is willing and able to sign the IRB approved Informed Consent form or able to provide Informed Consent in accordance with 21 CFR 50 CFR 50 Subpart B.
  • Subject is able to understand and follow study sample collection procedure.

排除标准

  • Subject has undergone a surgical resection or diversion procedure.
  • Subject is currently taking NSAIDS (non-steroidal anti-inflammatory drugs, i.e. ibuprofen, Advil, Motrin, Naproxen, Aleve including regular dose and low dose aspirin) within 7 days of colonoscopy and sample collection.
  • Subject who has taken immunomodulators or biologic therapies within the previous 6 months of colonoscopy and sample collection.
  • Subject who is currently pregnant or lactating.
  • Subject is unable or unwilling to follow informed consent.
  • Inability or unwilling to perform required study procedures.

结局指标

主要结局

Calprotectin Stool Collection

时间窗: Through Study Completion, an average of 1 year

In vitro diagnostic (IVD) device performance

次要结局

未报告次要终点

研究者

发起方
DiaSorin Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验

Fecal Calprotectin Collection Protocol | 临床试验